25-vitamin D, 1,25-vitamin D, parathyroid hormone, fibroblast growth factor-23 and cognitive function in men with advanced CKD: A veteran population

Clinical Nephrology

Volumn 82, Issue 5, 2014, Pages 296-303

  Jovanovich, Anna ^a   Chonchol, Michel ^a   Brady, Christopher B ^b   Kaufman, James D ^b   Kendrick, Jessica ^a   Cheung, Alfred K ^b,c   Jablonski, Kristen L ^a  

^a UNIVERSITY OF COLORADO   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c UNIVERSITY OF UTAH   (United States)

Author keywords

Chronic hemodialysis; Chronic kidney disease; Cognition; Mineral metabolism

Indexed keywords

25 HYDROXYVITAMIN D; CALCITRIOL; FIBROBLAST GROWTH FACTOR 23; PARATHYROID HORMONE; FOLIC ACID; HOMOCYSTEINE;

AGED; ARTICLE; CHRONIC KIDNEY DISEASE; COGNITION; DIALYSIS; END STAGE RENAL DISEASE; FEMALE; FOLLOW UP; HUMAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MINERAL METABOLISM; PARATHYROID HORMONE BLOOD LEVEL; TELEPHONE INTERVIEW; VETERAN; VITAMIN BLOOD LEVEL; ADULT; AGE; AMINO ACID BLOOD LEVEL; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CREATININE CLEARANCE; DIET RESTRICTION; DISEASE ASSOCIATION; POST HOC ANALYSIS; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK REDUCTION; SURVIVAL RATE;

EID: 84909644036     PISSN: 03010430     EISSN: None     Source Type: Journal    
DOI: 10.5414/CN108365     Document Type: Article

References (41)

1. Yaffe K, Ackerson L, Kurella Tamura M, Le Blanc P, Kusek JW, Sehgal AR, Cohen D, Anderson C, Appel L, Desalvo K, Ojo A, Seliger S, Robinson N, Makos G, Go AS; Chronic Renal Insufficiency Cohort Investigators. Chronic kidney disease and cognitive function in older adults: findings from the chronic renal insufficiency cohort cognitive study. J Am Geriatr Soc. 2010; 58: 338-345.
2. Khatri M, Nickolas T, Moon YP, Paik MC, Rundek T, Elkind MS, Sacco RL, Wright CB. CKD associates with cognitive decline. J Am Soc Nephrol. 2009; 20: 2427-2432.
3. Pereira AA, Weiner DE, Scott T, Sarnak MJ. Cognitive function in dialysis patients. Am J Kidney Dis. 2005; 45: 448-462.
4. Sehgal AR, Grey SF, DeOreo PB, Whitehouse PJ. Prevalence, recognition, and implications of mental impairment among hemodialysis patients. Am J Kidney Dis. 1997; 30: 41-49.
5. Brookmeyer R, Gray S, Kawas C. Projections of Alzheimer's disease in the United States and the public health impact of delaying disease onset. Am J Public Health. 1998; 88: 1337-1342.
6. Seliger SL, Sarnak MJ. Subclinical vascular disease of the brain in dialysis patients. Am J Kidney Dis. 2007; 50: 8-10.
7. Wada M, Nagasawa H, Iseki C, Takahashi Y, Sato H, Arawaka S, Kawanami T, Kurita K, Daimon M, Kato T. Cerebral small vessel disease and chronic kidney disease (CKD): results of a cross-sectional study in community-based Japanese elderly. J Neurol Sci. 2008; 272: 36-42.
8. Madero M, Gul A, Sarnak MJ. Cognitive function in chronic kidney disease. Semin Dial. 2008; 21: 29-37.
9. Prins ND, van Dijk EJ, den Heijer T, Vermeer SE, Jolles J, Koudstaal PJ, Hofman A, Breteler MM. Cerebral small-vessel disease and decline in information processing speed, executive function and memory. Brain. 2005; 128: 2034-2041.
10. Markus HS. Genes, endothelial function and cerebral small vessel disease in man. Exp Physiol. 2008; 93: 121-127.
11. Weiner DE. The cognition-kidney disease connection: lessons from population-based studies in the United States. Am J Kidney Dis. 2008; 52: 201-204.
12. Murray AM. The brain and the kidney connection: A model of accelerated vascular cognitive impairment. Neurology. 2009; 73: 916-917.
13. Kidney Disease; Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl. 2013; 3: 1-163.
14. Yilmaz MI, Sonmez A, Saglam M, Yaman H, Kilic S, Demirkaya E, Eyileten T, Caglar K, Oguz Y, Vural A, Yenicesu M, Zoccali C. FGF-23 and vascular dysfunction in patients with stage 3 and 4 chronic kidney disease. Kidney Int. 2010; 78: 679-685.
15. London GM, Guérin AP, Verbeke FH, Pannier B, Boutouyrie P, Marchais SJ, Mëtivier F. Mineral metabolism and arterial functions in end-stage renal disease: potential role of 25-hydroxyvitamin D deficiency. J Am Soc Nephrol. 2007; 18: 613-620.
16. Chitalia N, Recio-Mayoral A, Kaski JC, Banerjee D. Vitamin D deficiency and endothelial dysfunction in non-dialysis chronic kidney disease patients. Atherosclerosis. 2012; 220: 265-268.
17. Brady CB, Gaziano JM, Cxypoliski RA, Guarino PD, Kaufman JS, Warren SR, Hartigan P, Goldfarb DS, Jamison RL. Homocysteine lowering and cognition in CKD: the Veterans Affairs homocysteine study. Am J Kidney Dis. 2009; 54: 440-449.
18. Jamison RL, Hartigan P, Gaziano JM, Fortmann SP, Goldfarb DS, Haroldson JA, Kaufman J, Lavori P, McCully KS, Robinson K. Design and statistical issues in the homocysteinemia in kidney and end stage renal disease (HOST) study. Clin Trials. 2004; 1: 451-460.
19. Jamison RL, Hartigan P, Kaufman JS, Goldfarb DS, Warren SR, Guarino PD, Gaziano JM, Veterans Affairs Site Investigators. Effect of homocysteine lowering on mortality and vascular disease in advanced chronic kidney disease and end-stage renal disease: a randomized controlled trial. JAMA. 2007; 298: 1163-1170.
20. Welsh KA. Detection of early dementia in the elderly. Exp Aging Res. 1991; 17: 101
21. Järvenpää T, Rinne JO, Räihä I, Koskenvuo M, Löppönen M, Hinkka S, Kaprio J. Characteristics of two telephone screens for cognitive impairment. Dement Geriatr Cogn Disord. 2002; 13: 149-155.
22. Plassman BL, Newman TT, Welsh KA, Helms M, Breitner JCS. Properties of the Telephone interview for cognitive status -Application in epidemiologic and longitudinal-studies. Neuropsychiatry Neuropsychol Behav Neurol. 1994; 7: 235-241.
23. Jonsson KB, Zahradnik R, Larsson T, White KE, Sugimoto T, Imanishi Y, Yamamoto T, Hampson G, Koshiyama H, Ljunggren O, Oba K, Yang IM, Miyauchi A, Econs MJ, Lavigne J, Jüppner H. Fibroblast growth factor 23 in oncogenic osteomalacia and X-linked hypophosphatemia. N Engl J Med. 2003; 348: 1656-1663.
24. Smith ER, Ford ML, Tomlinson LA, Weaving G, Rocks BF, Rajkumar C, Holt SG. Instability of fibroblast growth factor-23 (FGF-23): implications for clinical studies. Clin Chim Acta. 2011; 412: 1008-1011.
25. Smith ER, Cai MM, McMahon LP, Holt SG. Biological variability of plasma intact and C-terminal FGF23 measurements. J Clin Endocrinol Metab. 2012; 97: 3357-3365.
26. Buell JS, Dawson-Hughes B. Vitamin D and neurocognitive dysfunction: preventing "D"ecline? Mol Aspects Med. 2008; 29: 415-422.
27. Jablonski KL, Chonchol M, Pierce GL, Walker AE, Seals DR. 25-Hydroxyvitamin D deficiency is associated with inflammation-linked vascular endothelial dysfunction in middle-aged and older adults. Hypertension. 2011; 57: 63-69.
28. Vendemiale G, Romano AD, Dagostino M, de Matthaeis A, Serviddio G. Endothelial dysfunctio associated with mild cognitive impairment in elderly population. Aging Clin Exp Res. 2013; 25: 247-255.
29. Lee DM, Tajar A, Ulubaev A, Pendleton N, O'Neill TW, O'Connor DB, Bartfai G, Boonen S, Bouillon R, Casanueva FF, Finn JD, Forti G, Giwercman A, Han TS, Huhtaniemi IT, Kula K, Lean ME, Punab M, Silman AJ, Vanderschueren D, Wu FC; EMAS study group. Association between 25-hydroxyvitamin D levels and cognitive performance in middle-aged and older European men. J Neurol Neurosurg Psychiatry. 2009; 80: 722-729.
30. Llewellyn DJ, Lang IA, Langa KM, Muniz-Terrera G, Phillips CL, Cherubini A, Ferrucci L, Melzer D. Vitamin D and risk of cognitive decline in elderly persons. Arch Intern Med. 2010; 170: 1135-1141.
31. Slinin Y, Paudel M, Taylor BC, Ishani A, Rossom R, Yaffe K, Blackwell T, Lui LY, Hochberg M, Ensrud KE; Study of Osteoporotic Fractures Research Group. Association between serum 25(OH) vitamin D and the risk of cognitive decline in older women. J Gerontol A Biol Sci Med Sci. 2012; 67: 1092-1098.
32. McGrath J, Scragg R, Chant D, Eyles D, Burne T, Obradovic D. No association between serum 25-hydroxyvitamin D3 level and performance on psychometric tests in NHANES III. Neuroepidemiology. 2007; 29: 49-54.
33. Shaffi K, Tighiouart H, Scott T, Lou K, Drew D, Weiner D, Sarnak M. Low 25-hydroxyvitamin D levels and cognitive impairment in hemodialysis patients. Clin J Am Soc Nephrol. 2013; 8: 979-986.
34. Arieff AI, Massry SG. Calcium metabolism of brain in acute renal failure. Effects of uremia, hemodialysis, and parathyroid hormone. J Clin Invest. 1974; 53: 387-392.
35. Akmal M, Goldstein DA, Multani S, Massry SG. Role of uremia, brain calcium, and parathyroid hormone on changes in electroencephalogram in chronic renal failure. Am J Physiol. 1984; 246: F575-F579.
36. Walker MD, McMahon DJ, Inabnet WB, Lazar RM, Brown I, Vardy S, Cosman F, Silverberg SJ. Neuropsychological features in primary hyperparathyroidism: a prospective study. J Clin Endocrinol Metab. 2009; 94: 1951-1958.
37. Roman S, Sosa JA. Psychiatric and cognitive aspects of primary hyperparathyroidism. Curr Opin Oncol. 2007; 19: 1-5.
38. Jorde R, Waterloo K, Saleh F, Haug E, Svartberg J. Neuropsychological function in relation to serum parathyroid hormone and serum 25-hydroxyvitamin D levels. The Tromsø study. J Neurol. 2006; 253: 464-470.
39. Jassal SV, Devins GM, Chan CT, Bozanovic R, Rourke S. Improvements in cognition in patients converting from thrice weekly hemodialysis to nocturnal hemodialysis: a longitudinal pilot study. Kidney Int. 2006; 70: 956-962.
40. Drew DA, Tighiouart H, Scott TM, Lou KV, Fan L, Shaffi K, Weiner DE, Sarnak MJ. FGF-23 and cognitive performance in hemodialysis patients. Hemodial Int. 2014; 18: 78-86.
41. Liu P, Chen L, Bai X, Karaplis A, Miao D, Gu N. Impairment of spatial learning and memory in transgenic mice overexpressing human fibroblast growth factor-23. Brain Res. 2011; 1412: 9-17.